Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorMontreal Heart Institute
About this trial
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years;
Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
Coronary angiogram performed;
Planned for medical management alone, without revascularization;
Disqualifiers
Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
Confirmed or suspected spontaneous coronary artery dissection;
Trial design
Design model
Parallel
Treatments tested in this trial
Ticagrelor + placebo
DrugTicagrelor 90 mg twice daily + placebo once daily
Ticagrelor + aspirin
DrugTicagrelor 90 mg twice daily + aspirin 80 mg once daily
Treatment groups
2,570 Participants
are divided into 2 treatment groupsGroup A: Ticagrelor monotherapyExperimental treatment 1 intervention
Group B: DAPT with ticagrelor and aspirinActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Bleeding
Time to first BARC type 2, 3, or 5 bleeding
Time frame
From randomization to 12 months2
Patient-oriented ischemic clinical endpoint
Time to first composite of all-cause mortality, MI, stroke, or any coronary revascularization
Time frame
From randomization to 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Montreal Heart Institute
Lead sponsor
Université de Montréal
Sponsor institution
Source ClinicalTrials.gov